Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis

• Published in: Menopause (New York, N.Y.) Vol. 16; no. 5; pp. 984 - 991
• Main Authors: Castelo-Branco, Camil, Ciria-Recasens, Manel, Cancelo-Hidalgo, María J., Palacios, Santiago, Haya-Palazuelos, Javier, Carbonell-Abelló, Jordi, Blanch-Rubió, Josep, Martínez-Zapata, María J., Manasanch, José, Pérez-Edo, Lluís
• Format: Journal Article
• Language: English
• Published: United States The North American Menopause Society 01-09-2009
• Subjects: Administration, Oral; Bone Density - drug effects; Bone Diseases, Metabolic - prevention & control; Bone Resorption - prevention & control; Calcium Carbonate - pharmacology; Calcium Carbonate - therapeutic use; Durapatite - pharmacology; Durapatite - therapeutic use; Evidence-Based Practice; Humans; Osteoporosis - prevention & control; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome
• ISSN: 1072-3714; 1530-0374
• DOI: 10.1097/gme.0b013e3181a1824e

OBJECTIVE:There is increasing evidence to suggest that ossein-hydroxyapatite complex (OHC) is more effective than calcium supplements in maintaining bone mass. The aim of this meta-analysis was to determine whether OHC has a different clinical effect on bone mineral density (BMD) compared with calcium carbonate (CC).
METHODS:A meta-analysis of randomized controlled clinical trials was carried out to evaluate the efficacy of OHC versus CC on trabecular BMD. We identified publications on clinical trials by a search of electronic databases, including MEDLINE (1966-November 2008), EMBASE (1974-November 2008), and the Cochrane Controlled Clinical Trials Register.The primary endpoint was percent change in BMD from baseline. Data were pooled in a random-effects model, and the weighted mean difference was calculated. A sensitivity analysis that excluded trials without full data was performed.
RESULTS:Of the 18 controlled trials initially identified, 6 were included in the meta-analysis. There was no significant heterogeneity among the included trials. The percent change in BMD significantly favored the OHC group (1.02% [95% CI, 0.63-1.41], P < 0.00001). These results were confirmed in the sensitivity analysis.
CONCLUSIONS:OHC is significantly more effective in preventing bone loss than CC.